Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

View From The Top: Growing Grünenthal

Executive Summary

As he leaves after 23 years at the firm, outgoing CEO Eric-Paul Pâques talks about Grünenthal's growth and strategic priorities under his leadership while its new head, Gabriel Baertschi, brings his own brand of energy.

You may also be interested in...



Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.

Grünenthal New CEO: My Strategic Priorities

Gabriel Baertschi, the new head of midsize German pharma firm Grünenthal talks to Jo Shorthouse about his first moves as CEO

Grünenthal On Hunt For Asia Partner As Pain Killer Hits Phase III Endpoints

Grünenthal’s novel pain killer has succeeded in a Phase III trial in cancer pain and now the company wants to find a partner for Asian markets, to complement its deal last year with Depomed for North America.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131647

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel